Human Genome reports Phase II data

Preliminary data from a 94-patient Phase II trial of HGSI's topical repifermin keratinocyte growth factor-2 (KGF-2) to treat chronic venous ulcers showed the compound was well tolerated, with similar adverse events to placebo. Repifermin also was active based on various wound healing parameters, including the percentage of patients achieving partial wound closure and total area of the wound healed. ...